Data and Publications. (a) Jestliže je klinické hodnocení prováděno jako součást multicentrického klinického hodnocení, bude mít první publikace výsledků klinického hodnocení formu multicentrické publikace, jejímiž autory budou zkoušející tohoto klinického hodnocení. Pokud ovšem nebude multicentrická publikace předložena do osmnácti (18) měsíců od dokončení nebo předčasného ukončení klinického hodnocení ve všech centrech, smí zdravotnické zařízení a zkoušející publikovat výsledky klinického hodnocení ze zdravotnického zařízení v souladu s tímto článkem. (a) If the Study is being conducted as part of a multi- center clinical trial, the first publication of the results of the Study shall be in the form of a multi-center publication authored by investigators in this Study. However, if a multi-center publication is not submitted within eighteen (18) months following completion or termination of the Study at all sites, Institution and Investigator may publish Institution’s Study results in accordance with this Section.
Data and Publications. 1. This Cooperative Agreement is subject to, and Recipient shall comply with, 32 CFR Subpart 32.6 concerning “Intangible Property,” which includes use of research data. Any information or data protected by federal law will be identified by the Government prior to being provided to Recipient and the Government will notify the Recipient in advance of applicable limitations on such information. Except as to information so identified and limited, there are no restrictions on reporting or publishing reports based upon the fundamental research that is the subject of this Cooperative Agreement. The Federal Government has the right to obtain, reproduce, publish or otherwise use the data first produced under this Agreement and authorize others to receive, reproduce, publish, or otherwise use such data for Federal purposes. The DoN acknowledges and agrees that the Recipient’s fundamental consideration in performing the research under this Agreement shall be Recipient’s right to publish the results of such research for academic and scientific purposes. The Recipient shall submit, for review and comment, any proposed professional, scientific or non-scientific report, paper or note published or unpublished or be part of any technical or non-technical presentation or be provided to anyone not a party to this Agreement to the CATR and USMC thirty (30) days prior to the submission of the work mentioned above. The Recipient shall retain lead authorship publication rights to the original research for a period of three (3) years following submission of the final report. These rights shall revert to the USMC should the Recipient fail to do so within the three (3) years. The USMC also retains the right to publish any re-analysis of the data.
Data and Publications. The parties shall jointly own and shall be free to reproduce, publish, and use for any lawful purpose, any data produced by the Research Projects, subject to the publication requirements set forth in this Section 13. Each party will be free to publish the results of any and all Research Projects under this Agreement after providing a copy of each proposed publication to the other party at least thirty (30) days prior to the submission for publication for the other party to review the publication alld provide any comments. If a party reasonably believes that a disclosure of patentable material is contained in the proposed publication, the parties will work together to protect to the extent reasonably practicable any potentially patentable subject matter prior to such publication in a manner consistent with Section 15 below. The parties shall delay such publication to the extent reasonably necessary to protect such potentially patentable subject matter, such delay not to exceed thirty (30) days in the case of subject matter the patent prosecution of which is not under DEI's control hereunder. Further, each party shall have the right to redact from any publication its Confidential Information to the extent the publishing party has all obligation to keep it confidential pursuant to Section 12 above. Any publication resulting from work performed under this Agreement shall acknowledge the contributions of DEI and the support of the NIH or other grant awarding agency (if applicable) and SSMP. For the avoidal1ce of doubt, any and all publications related to the Research Products shall be subject to review and approval under this paragraph.
Data and Publications. 4.1. Data. You hereby grant to the Company, and any third party the Company has contracted with to provide storage and processing services, a nonexclusive, non-transferable licence to store, process and use any Publications, your Data and your Users’ Data for the purpose of providing the Services and for the purpose of generating Analytical Data as described at Section 4.2 below. You shall (a) be responsible for obtaining consent from the Users as necessary to store, process and use your Users’ Data in the Service and each of your Users’ compliance with this MSA; (b) be responsible for the consent, accuracy, quality and legality of your and the Users’ Data and Publications and of the means by which you or they acquired such Data and Publications; (c) provide the Company such reasonable assistance as the Company may request in order to assist you on your integration of your Data into the Service, and (d) ensure that the Users shall comply with applicable laws and government regulations.
Data and Publications. Institution and/or Investigator shall have the right to publish and present the results of the Study provided: Institution and Investigator shall not disclose Sponsor’s confidential and proprietary technical information; Institution and Investigator shall not publish or present Study results from a single site prior to completion of the Study at all sites participating in the Study; and/or Institution and Investigator, at the request of Sponsor, shall delay publication or presentation as provided in subparagraph (d) below. Institution acknowledges and agrees that the Study is being conducted as part of a multi-center clinical trial, that data from all sites will be pooled and analyzed, and that disclosure of data from a single site may be misleading. Sponsor shall have the right to publish any data and information from the Study (including data and information generated by Investigator) without the consent of Institution or Investigator. Institution and/or Investigator will provide Sponsor with a copy of any proposed publication or presentation for review and comment at least sixty (60) days prior to such presentation or submission for publication. At the expiration of such sixty (60) day period, Institution and/or Investigator may proceed with the presentation or submission for publication unless Sponsor has notified Institution and/or Investigator in writing that such proposed publication and/or presentation discloses Sponsor’s confidential and proprietary technical information. Sponsor shall inform Institution and/or Investigator in writing of any changes or deletions in such presentation or publication necessary to protect Sponsor’s confidential and proprietary technical information and Institution and Investigator hereby agree to make any such changes or deletions prior to publication. Further, upon the request of Sponsor, Institution and Investigator will delay publication or presentation (A) for up to ninety (90) days to permit Sponsor to take necessary actions to protect its intellectual property interests, and (B) until the Study has been completed at all sites participating in the Study and properly analyzed. (e) Institution, without any additional compensation, agrees to assist Sponsor in obtaining reprints of any Institution and/or Investigator publication(s) resulting from the Study. 11.
Data and Publications. 1. The Cooperator acknowledges that information and data gathered or received pursuant to the Agreement may have regulatory and national security significance and that the unauthorized dissemination or use of this information might prejudice the interests of the U.S. Navy and Department of Defense. Therefore, the Cooperator agrees not to disclose or use any information or data directly or indirectly acquired through activities associated with the Agreement to any person, organization or entity who is not a party to the Agreement, and to prohibit disclosure or use of the same by the Cooperator’s personnel, representatives, agents, contractors, or associates unless disclosure is compelled by process of law, or the Navy authorizes disclosure or use in accordance with this Section of the Agreement. The terms “data”, “information,” “use” and “disclose” (and its forms and derivatives) will be interpreted very broadly.
Data and Publications. (a) Institution and/or Investigator shall have the right to publish and present the results of the Study provided:
Data and Publications. 21B11. A. Údaje a publikace. 145B(a) If the Study is being conducted as part of a multi-center clinical trial, the first publication of the results of the Study shall be in the form of a multi-center publication authored by investigators in this Study. However, if a multi-center publication is not submitted within eighteen (18) months following completion or termination of the Study at all sites, Institution and Investigator may publish Institution’s Study results in accordance with this Section. 146B(a) Pokud je prováděné klinické hodnocení součástí multicentrického klinického hodnocení, první publikace výsledků klinického hodnocení bude mít formu multicentrické publikace, jejímiž autory budou zkoušející lékaři v tomto klinickém hodnocení. Pokud však multicentrická publikace nebude předložena během osmnácti (18) měsíců od dokončení nebo ukončení klinického hodnocení ve všech centrech, zdravotnické zařízení a zkoušející lékař smí publikovat výsledky zdravotnického zařízení v klinickém hodnocení v souladu s touto částí. 147B(b) Investigator and Institution will provide Sponsor with a copy of any proposed publication or presentation for review and comment at least forty-five (45) days prior to such presentation or submission for publication. At the expiration of such forty (45) day period, Investigator and Institution may proceed with the presentation or submission for publication unless Sponsor has notified Investigator and Institution in writing that such proposed publication and/or presentation discloses Confidential Information. Investigator and Institution hereby agree to make any changes or deletions prior to publication necessary to prevent disclosure of Confidential Information. Further, upon the request of Xxxxxxx, Investigator and Institution will delay publication or presentation an additional ninety (90) days to permit Sponsor to take necessary 148B(b) Zkoušející lékař a zdravotnické zařízení poskytnou zadavateli ke kontrole a okomentování kopii jakékoli navrhované publikace nebo prezentace nejméně čtyřicet pět (45) dní před takovou prezentací nebo odesláním k publikaci. Po uplynutí tohoto čtyřicetipětidenního (45) období může zkoušející lékař a zdravotnické zařízení pokračovat s prezentací nebo odesláním k publikaci, pokud zadavatel zkoušejícímu lékaři a zdravotnickému zařízení písemně nesdělil, že tato navržená publikace anebo prezentace prozrazuje důvěrné informace. Zkoušející lékař a zdravotnické zařízení tímto souhlasí, že před zveřejněním p...
Data and Publications. (a) The Institution and/or the Investigator shall have the right to publish and present the results of the Study provided: (i) The Institution and the Investigator shall not disclose the Sponsor’s confidential and proprietary technical information; (ii) The Institution and the Investigator shall not publish or present Study results from a single site prior to completion of the Study at all sites participating in the Study; and/or (iii) The Institution and the Investigator, at the request of the Sponsor, shall delay 10. Údaje a publikácie. (a) Skúšajúci a zdravotnícke zariadenie majú právo publikovať a prezentovať výsledky zo skúšania za nasledujúcich predpokladov: (i) Skúšajúci a zdravotnícke zariadenie nebudú odhaľovať dôverné technické informácie zadávateľa chránené vlastníckymi právami; (ii) Skúšajúci a zdravotnícke zariadenie nebudú publikovať ani prezentovať výsledky skúšania z jedného centra dovtedy, kým sa skúšanie nedokončí vo všetkých centrách, ktoré sa ho
Data and Publications. 11.1. Nothing herein shall prevent either Party from making publications relating solely to their own Intellectual Property. Notwithstanding the above, a Party wishing to make a publication which in any way relates to or references the other Party's Intellectual Property shall not be permitted to make such publication unless it has transmitted to the other Party a copy of the proposed publication and received the other Party's advance written approval to publicize such publication, which shall not be unreasonably withheld. The other Party may: (i) approve conditionally or unconditionally such publication, or (ii) withhold approval for such publication. It is agreed the prevention of publication of a Party's Confidential Information shall be considered as reasonable reason for denial of publication. 11.2. Without derogating from the above, the Parties shall cooperate in good faith in order to agree on the form of an initial publication of their engagement under this Agreement (including the Development and Evaluation Program). 11.3. Notwithstanding the above: (i) OWC shall be entitled to freely publicize the results of the Trial in any scientific publication or symposium without obtaining Emilia's prior written consent; and (ii) nothing herein shall be construed as prohibiting a Party from making any disclosure required under applicable law (including any securities laws) or valid court order. 12.
